,33, 34, 35 The AIRTRIP (Anakinra Treatment of Recurrent Idiopathic Pericarditis) study was the first clinical trial of IL-1 pathway inhibition in RP; it demonstrated that anakinra (with/without concomitant colchicine), when used third line in flaring colchicine-resistant corticosteroid-dependent idiopathic RP patients, significantly reduced the risk of recurrence compared with placebo; 90% (9/10) of patients receiving placebo experienced a recurrence vs 18% (2/11) in those receiving anakinra. This evidence concerns the gene IL1A and retinitis pigmentosa 1.